• Back To Industries Listing
• Practice Areas
• Industries

• Biotechnology
• Diagnostics
• Financial Services
• Life Sciences
• Medical Devices
• Therapeutics

• Intellectual Property
• Litigation
• Patents
• Technology & IP Litigation

• Jeffrey E. Francis
• Franklin B. Velie

Pharmaceutical

It is clear that the pharmaceutical industry is in the midst of massive growth, upheaval, consolidation and change. Global sales of prescription and over-the-counter drugs are topping $300 billion annually. With increased life expectancies, we are dealing with an increasingly aged population consuming on average three times as many drugs as the younger population. R&D costs are on the rise — changing the scope of products drug companies focus on developing — and patent prosecutions continue daily as drug companies try to manage their portfolios of expiring patents. Already we are seeing consolidation in the industry through mega mergers and acquisitions to pool R&D capabilities and patent range - it's clear the pharmaceutical industry is set to continue to change. For our clients, staying one step ahead of these changes is imperative to their success.

Our lawyers works with pharmaceutical clients ranging in size from university funded operations to one of the top five pharmaceutical companies in the U.S. For these clients, we help them face their daily challenges and plans for the future by assisting their funding efforts, negotiating contracts, guiding them potential through merger & acquisition deals, managing patent due diligence and prosecution, arbitration and litigation.

Representative Client Work

• Ongoing counsel to major pharmaceutical company with respect to suspected theft of trade secrets
• Successfully defended to multimillion dollar breach of contract claim arising from sale of pharmaceutical and medical supply company resulting in favorable settlement for client
• Represented a multi-national pharmaceutical company in an international arbitration involving a distribution agreement, and in litigation involving ownership of a drug in development